Egetis Therapeutics AB (publ) Total Current Liabilities

Egetis Therapeutics AB (publ) (EGTX.ST) currently reports a total current liabilities of $270M as of June 2026. That compares with $230M in the prior-year period — up 17.6% year over year. Use the charts on this page to explore Egetis Therapeutics AB (publ)'s total current liabilities history and peer comparisons.

Egetis Therapeutics AB (publ)'s total current liabilities increased from $230M to $270M — a 17.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Egetis Therapeutics AB (publ) reported $270M in total current liabilities as of June 2026. That compares with $230M in the prior-year period — up 17.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $270M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Egetis Therapeutics AB (publ), and consider following EGTX.ST for alerts when major investors trade the stock.

Egetis Therapeutics AB (publ) is classified in the Healthcare sector. On total current liabilities, it currently shows $270M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EGTX.ST with unrelated industries.